// App-Quantinova.ai

: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy

Researchers

Presenter

  • G. Chi

Principal Investigators

  • T. Nafee

  • S. Korjian

  • Y. Daaboul

  • R.A. Harrington

  • S.Z. Goldhaber

  • R.D. Hull

  • A. Gold

  • A.T. Cohen

  • C.M. Gibson

Medical Centers

  • Beth Israel Deaconess Medical Center, Harvard Medical School, Cardiovascular Division, Department of Medicine, Boston, United States of America

  • School of Medicine, Department of Medicine, Stanford, United States of America

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • University of Calgary, Gastroenterology, Calgary, Canada

  • Portola Pharmaceuticals, Inc., South San Francisco, United States

  • Guy's Hospital, Department of Haematological Medicine, London, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • betrixaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Portola Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved